Background
Phase 2, single-institution, single-arm, open-label trial (MD Anderson). N=84 patients aged ≥60 years with newly diagnosed Philadelphia chromosome-negative B-cell ALL. Mini-hyper-CVD (reduced-intensity cyclophosphamide + vincristine + dexamethasone, alternating with reduced-dose methotrexate and cytarabine) plus inotuzumab ozogamicin (InO; CD22-targeted antibody-drug conjugate) given in cycles 1–4; later cohorts added blinatumomab consolidation. Long-term 7-year analysis published Lancet Haematol 2023.
Interventions and follow up
Regimen: Mini-hyperCVD (cyclophosphamide 150 mg/m² Q12h × 6 doses days 1–3, dexamethasone 20 mg days 1–4 and 11–14, vincristine 2 mg days 1+11; methotrexate 250 mg/m² + cytarabine 0.5 g/m² Q12h × 4 doses on even cycles) + inotuzumab ozogamicin 1.3–1.8 mg/m² cycle 1 then 1 mg/m² thereafter (cycles 1–4)
Later cohorts: ± blinatumomab consolidation (post-InO cycles)
Population: Newly diagnosed Ph-negative B-ALL age ≥60
Primary endpoint: Complete remission (CR)/CRi rate
Median follow-up: 7 years (long-term update)
Later cohorts: ± blinatumomab consolidation (post-InO cycles)
Population: Newly diagnosed Ph-negative B-ALL age ≥60
Primary endpoint: Complete remission (CR)/CRi rate
Median follow-up: 7 years (long-term update)
Results
CR/CRi rate: 98% (82/84)
MRD-negative (among responders): 82%
mOS (all 84 patients): 17 months (95% CI 13–30); 7-year OS 34%
mDFS: 6.7 months (95% CI 5.1–12.3); 7-year DFS 34%
Allo-HSCT in CR1: 14% (very low, a major advantage for this elderly population)
Hepatic VOD/SOS: 10.7% (9/84), including fatal events post-transplant
MRD-negative (among responders): 82%
mOS (all 84 patients): 17 months (95% CI 13–30); 7-year OS 34%
mDFS: 6.7 months (95% CI 5.1–12.3); 7-year DFS 34%
Allo-HSCT in CR1: 14% (very low, a major advantage for this elderly population)
Hepatic VOD/SOS: 10.7% (9/84), including fatal events post-transplant
Adverse events
Hepatic: VOD/SOS 10.7% any grade (9/84), higher in patients proceeding to allo-HSCT; hepatotoxicity (bilirubin elevation) ~20% grade ≥3
Hematologic/infectious: Thrombocytopenia grade ≥3 ~70%; infections grade ≥3 ~50%; prolonged cytopenias common
Overall: Treatment-related mortality ~5%; mini-hyperCVD avoids the severe mucositis and cardiotoxicity of full hyperCVAD
Hematologic/infectious: Thrombocytopenia grade ≥3 ~70%; infections grade ≥3 ~50%; prolonged cytopenias common
Overall: Treatment-related mortality ~5%; mini-hyperCVD avoids the severe mucositis and cardiotoxicity of full hyperCVAD
Conclusions
Mini-hyper-CVD + inotuzumab ozogamicin achieved 98% CR/CRi with 82% MRD-negativity in patients ≥60 years with newly diagnosed Ph-negative B-ALL — markedly superior to historical hyperCVAD outcomes in this age group. Seven-year OS of 34% with very low transplant use is a clinically meaningful achievement for elderly ALL. VOD/SOS (11%) remains the key toxicity concern, particularly for patients who proceed to allo-HSCT.
Key Limitations
Single-arm, single-institution phase 2 design without a randomized comparator limits causal inference; outcomes are benchmarked against historical controls. The modest median OS (17 months) despite the very high CR rate reflects substantial relapse and treatment-related mortality in this frail elderly population. VOD/SOS at ~11%, with fatal cases in transplanted patients, is a major safety concern that constrains subsequent allo-HSCT. Sequential addition of blinatumomab in later cohorts confounds interpretation of the inotuzumab contribution. Results require confirmation in multicenter randomized trials.
Clinical Context
This regimen established low-intensity chemoimmunotherapy as a leading approach for older adults with newly diagnosed Ph-negative B-ALL, a population poorly served by full-dose hyperCVAD. Inotuzumab ozogamicin is FDA-approved for relapsed/refractory B-ALL; its frontline use in older adults here is investigational but widely adopted at high-volume centers. ESMO and ASCO frameworks endorse antibody-drug conjugate and bispecific incorporation to reduce chemotherapy intensity in older ALL. VOD risk mandates caution when bridging to transplant. ESMO-MCBS: not assigned.
References